The problem
Progress has been made in increasing life expectancy and fighting against leading communicable diseases, but progress has stalled in addressing major diseases such as malaria and tuberculosis. More concerted efforts are required to tackle these diseases and others, including by addressing antimicrobial resistance and determinants of health such as air pollution and inadequate water and sanitation. Corporations play a central role in fighting disease, including in the drugs they choose to research and manufacture (for pharmaceutical companies); their contribution to non-communicable diseases (such as with unhealthy food and diabetes) and the fight against non-communicable diseases (such as research companies focused on cancers or heart diseases); the healthcare benefits they provide workers; charitable giving in the area of global health; and how they contribute to global economic growth (growth usually increases access to healthcare and some determinants of health such as water and sanitation, but may also increase determinants of health such as pollution)
How companies are rated
226K
Ethos is using 226,028 unique data points since 2017 to rate companies, stocks and funds on disease eradication, including from these metrics:
Financial performance
r =
+0.028
Company ratings 1-yr return
Top 10 for disease eradication
Top 50 for disease eradication
S&P 500 Index
Bottom 50 for disease eradication
Bottom 10 for disease eradication
Disease eradication has a slight positive correlation (
+0.028
) with financial returns, meaning companies that perform better in this impact area tend to perform slightly better financially
Data partners and sources
What this formula is about
Diseases
communicable diseases
non-communicable diseases
immunization
disease eradication
medicine
global health
UN Sustainable Development Goal 3